


Name of Sponsor: IRCCS OSPEDALE SAN RAFFAELE - Prof. Fabio Ciceri		Statement on discontinuation of the study	 I.R.C.C.S. Ospedale San Raffaele Gruppo San Donato
Investigational Product: Temsirrolimus		EudraCT No.: 2018-001741-14	
		Page: 1	
Report Date: 04/10/2022	Trial No. / Doc. No.: TEM-MM-101 - Version 3.0 – 23 November 2019		
Title of Trial:	A phase I/II dose escalation study evaluating safety and activity of autologous CD34+-enriched hematopoietic progenitor cells genetically modified with a lentiviral vector encoding for the human interferon- α 2 gene in multiple myeloma patients with early relapse after intensive front line therapy		
Trial Sites:	NA		
Publications:	NA		
Clinical Phase:	I/II		
Statement on discontinuation of the study:	Since the start of the study, only 3 patients have been enrolled: one of them failed to mobilize CD34 + cells, while 2 reached the apheresis process and the production of the advanced therapy medicine (ATMP).		